---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-22-000164"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:05:50.757014+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Carisma updates CT-0508 interim data; merger with Sesen expected to close in 1-2 months

## Summary
- Updated interim data from CT-0508 Study 101 supports safety profile and tumor infiltration.
- Carisma outlines six pre-clinical and clinical milestones expected in 2023.
- Merger with Sesen expected to close in 1-2 months, subject to stockholder approval.

## SEC filing metadata
- accession: 0001485003-22-000164
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000164/0001485003-22-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500322000164/sesn-20221212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-22-000164
- JSON: https://secwatch.observer/filing/0001485003-22-000164.json
- Plain text: https://secwatch.observer/filing/0001485003-22-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.